We are excited to be working with OpenBiome, the first public stool bank, to ensure perpetual access to fecal microbiota transplantation by seeking FDA approval for FIN-403.

Our collaboration leverages the quality infrastructure OpenBiome has already used in more than 20,000 C. difficile treatments. In addition to the technical benefits of building on this experience, working with OpenBiome provides an inspiring window into the direct impact that we can have on patients’ lives – every day, OpenBiome provides dozens of treatments for C. diff patients across the country, enabled by FDA’s compassionate use policy.

Our contractual relationship with OpenBiome is also an important demonstration of our long-term commitment to the field, as it ensures that our success will provide significant financial support for OpenBiome’s nonprofit mission to catalyze research in the microbiome.

To find out more about this collaboration, please visit